Perspectives on the Failure of Pharmaceutical and Medical Device Industries to Fully Protect Public Health Interests

American Journal of Cardiology

Volumn 100, Issue 1, 2007, Pages 147-151

  Maron, Barry J ^a   Hauser, Robert G ^a  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTICAL ERROR; ARTICLE; DEATH; DRUG INDUSTRY; ECONOMIC ASPECT; INFORMED CONSENT; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MEDICAL INSTRUMENTATION; PRIORITY JOURNAL; PUBLIC HEALTH; RISK;

EID: 34250829110     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.02.072     Document Type: Note

References (37)

1. Mirowski M., Reid P.R., Mower M.M., Watkins L., Gott V.L., Schauble J.F., Langer A., Heilman M.S., Kolenik S.A., Fischell R.E., and Weisfeldt M.L. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 303 (1980) 322-324
2. Maron B.J., Shen W.-K., Link M.S., Epstein A.E., Almquist A.K., Daubert J.P., Bardy G.H., Favale S., Rea R.F., Boriani G., et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 342 (2000) 365-373
3. Gornick C.C., Hauser R.G., Almquist A.K., and Maron B.J. Unpredictable implantable cardioverter-defibrillator pulse generator failure due to electrical overstress causing sudden death in a young high-risk patient with hypertrophic cardiomyopathy. Heart Rhythm 2 (2005) 681-683
4. Meier B. Maker of heart device kept flaw from doctors (2005), The New York Times May 24, A1, C3.
5. Steinbrook R. The controversy over Guidant's implantable defibrillators. N Engl J Med 353 (2005) 221-224
6. FDA issues nationwide notification of recall of certain Guidant implantable defibrillators and cardiac resynchronization therapy defibrillators (2005). http://www.fda.gov/bbs/topics/news/2005/new01185.html June 17, Available at: http://www.fda.gov/bbs/topics/news/2005/new01185.html. Accessed June 17, 2005.
7. Hauser R.G., and Maron B.J. Lessons from the failure and recall of an implantable cardioverter-defibrillator. Circulation 112 (2005) 2040-2042
8. Meier B. Behind heart implants, a history of defects and a repeated error (2005), The New York Times October 20, A1, C6
9. Meier B. Citing flaws, maker recalls heart devices. 29,000 Implanted units could short-circuit (2005), The New York Times June 18, A1, B12
10. FDA updates consumers on Guidant Corporation's implantable defibrillators. News release from the Food and Drug Administration, Rockville, Maryland, on July 1, 2005. Available at: http://www.fda/gov/bbs/topoics/news/2005/new01198.html. Accessed July 6, 2005.
11. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., Kvien T.K., Schnitzer T.J., and VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
12. Zarraga I.G.E., and Schwarz E.R. Coxibs and heart disease. What we have learned and what else we need to know. J Am Coll Cardiol 49 (2007) 1-14
13. Keane WF. Merck announces voluntary worldwide withdrawal of Vioxx, North Wales, Pennsylvania, September 30, 2004. Available at: http://www.vioxx.com/vioxx/documents/english/hcp_notification_physicians .pdf. Accessed December 28, 2005.
14. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., Lines C., Riddell R., Morton D., Lanas A., Konstam M.A., Baron J.A., and Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
15. Petersen M. Doubts are raised on the safety of two popular arthritis drugs (2001), The New York Times May 22, C1
16. Topol E.J. Failing the public health-rofecoxib, Merck, and the FDA. N Engl J Med 351 (2004) 1707-1709
17. Topol E.J., and Falk G.W. A coxib a day won't keep the doctor away. Lancet 364 (2004) 639-640
18. Mukherjee D.M., Nissen S.E., and Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 786 (2001) 954-959
19. Meier B. FDA had report of short circuit in heart devices (2005), The New York Times September 12, A1, A16
20. Meier B. Heart device sold despite flaw, data shows (2005), The New York Times June 2, C1, C4
21. Guidant letter to physicians: Prizm DR, 1861. May 23, 2005.
22. Meier B. Files show Guidant foresaw some risks (2005), The New York Times December 24, p. C-1
23. Myerburg R.J., Apostolakis G.E., Beller G.A., DiMarco J.P., Feigal D.W., Goodman K.W., Hunt S.A., Lindsay B.D., Maibach E.W., Naccarelli G.V., Teta M.J., and Verter J.I. Report of the independent panel of Guidant Corporation (2006). http://www.guidant.com/panel/panel.pdf March 20, Available at: http://www.guidant.com/panel/panel.pdf. Accessed May 10, 2006.
24. Myerburg R.J., Feigal Jr. D.W., and Lindsay B.D. Life threatening malfunction of implantable cardiac devices. N Engl J Med 354 (2006) 2309-2311
25. Meier B. Guidant papers show it considered warning doctors of flaws (2006), The New York Times June 7, C1, C2
26. Bresalier R.S., Friedewald Jr. V.E., Rakel R.E., Roberts W.C., and Williams G.W. The editor's roundtable: cyclooxygenase-2 inhibitors and cardiovascular risk. Am J Cardiol 96 (2005) 1589-1604
27. Curfman G.D., Morrissey S., and Drazen J.M. Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. (N Engl J Med 2000;343:1520-1528).". N Engl J Med 353 (2005) 2813-2814
28. Waxman H.A. The marketing of Vioxx to physicians (2005). http://www.democrats.reform.house.gov/features/vioxx/documents.asp May 5, Available at: http://www.democrats.reform.house.gov/features/vioxx/documents.asp. Accessed May 5, 2005.
29. Kim PS. An Open Letter from Merck, Whitehouse Station, NJ, December 15, 2005. Available at: http://www.merck.com/newsroom/vioxx_withdrawal/merck_letter.swf. Accessed December 15, 2005.
30. Berenson A. For Merck, Vioxx paper trail won't go away (2005), The New York Times August 21, A1
31. Mahar M. Money Driven Medicine. The Real Reason Health Care Costs So Much (2006), Harper-Collins, New York 303-308
32. United States Senate Committee on the Judiciary. Defective Products: Will Criminal Penalties Ensure Corporate Accountability? Barry J. Maron, MD Testimony: Need for reform in the medical device (implantable defibrillator) industry, Friday, March 10, 2006. Congressional Record - Daily Digest March 13, 2006:D224. Available at: http://wais.access.gpo.gov. Accessed April 15, 2006.
33. Meier B. Guidant settles suit on death of recipient of heart device (2005), The New York Times November 23, C7
34. Jordan G.E. Some FDA info allowed in Vioxx case. Judge delays ruling on one April notice (2005), The Star Ledger August 31, p. B-62
35. Heart Rhythm Society Task Force. Recommendations from the Heart Rhythm Society Task Force on Device Performance Policies and Guidelines. Heart Rhythm 3 (2006) 1251-1273
36. Proceedings Document from the Policy Conference on Pacemaker and ICD Performance presented by the Heart Rhythm Society and the Food and Drug Administration, September 16, 2005, Washington, DC. Available at: http://www.HRSonline.org/advocacyDocs/HRS-device_conference.pdf. Accessed September 28, 2005.
37. Meier B. FDA plans to intensify oversight of heart devices (2006), The New York Times. http://www.nytimes.com/2006/04/07/business/07device.html?ex=1302062400&e n=8585ea9669704e68&ei=5088&partner=rssnyt&emc=rss April 7, C7. Available at: http://www.nytimes.com/2006/04/07/business/07device.html?ex=1302062400 &en=8585ea9669704e68&ei=5088&partner=rssnyt&emc=rss. Accessed April 15, 2006.